- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01792245
Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand
Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial
Studie Overzicht
Gedetailleerde beschrijving
Hand dermatoses is a common problem which is characterized by itchy, erythematous and scaly lesions often with a long lasting and relapsing course. Patients presenting with these severe cutaneous changes are classified as having severe recalcitrant hand dermatoses. Treatment is difficult with considerable number of patients do not or only partially respond to the current treatments. Current treatment regimens mainly involve the use of high potency topical corticosteroids, which has only limited affect. Systemic treatment modalities have been utilized but have serious side effects with limited improvement of disease.
Several studies have shown the therapeutic effectiveness of the combination of topical psoralen with long wavelength ultraviolet A radiation (PUVA) in treating hand dermatoses. Topical PUVA is commonly associated with mild local sunburn reactions that often necessitate temporarily withholding treatment or decreasing the light dose. This subsequently leads to a delay in response or a prolongation of the treatment. Long term side effects include aging of the skin, hyperpigmentation, and a small increased risk of skin cancer that is more common in systemic PUVA. Narrow band ultraviolet B (NB-UVB) has emerged recently as an important treatment for a variety of photoresponsive diseases including psoriasis and eczema. For most conditions (other than hand psoriasis/eczema) NB-UVB has been shown to have similar therapeutic results to PUVA with less side effects.
There are only a few studies published on the efficacy of NB-UVB for hand psoriasis/eczema. Our hypothesis is that NB-UVB and topical PUVA will result in at least comparable improvement in hand psoriasis/eczema with less side effects associated with NB-UVB. We plan on conducting a prospective single-blind randomized clinical trial to compare the efficacy and safety of topical PUVA and NB-UVB in treating hand psoriasis/eczema.
Study Objectives
- To compare the effect of topical PUVA and NB-UVB on visual cutaneous symptoms in patients presenting with recalcitrant hand dermatoses.
- To compare the side effect profile of topical PUVA and NB-UVB when treating patients with recalcitrant hand dermatoses.
Studietype
Inschrijving (Verwacht)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Harvey Lui, MD, FRCPC
- E-mail: harvey.lui@ubc.ca
Studie Locaties
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E8
- Werving
- The Skin Care Center, Vancouver General Hospital
-
Contact:
- Harvey Lui, MD FRCPC
- Telefoonnummer: 16048754111
- E-mail: harvey.lui@ubc.ca
-
Hoofdonderzoeker:
- Sunil Kalia, MD FRCPC
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Chronic symmetrical severe hand psoriasis and eczema (allowing up to 15% difference in surface area between both hands). These include patients that have received topical corticosteroids previously and may or may have not responded to treatment.
- Subjects should be 18 years old or older.
Exclusion Criteria:
- Any serious medical illness that will restrict the patient's ability to receive light treatments. That includes skin conditions, such as skin cancer or severe blistering conditions, or any serious medical conditions affecting the sensation of the extremities (eg. diabetic neuropathy, cervical stenosis).
- Patients known to have a photosensitivity disorder
- Patients with a history of intolerance to UVB and/or UVA light therapy.
- Any subject who is on treatment or was on treatment for hand psoriasis/eczema less than two (topical) or four (systemic/phototherapy) weeks prior to enrollment in the study.
- Pregnancy or breast-feeding.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: NB-UVB
This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA.
For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB.
Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly.
Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
|
|
Actieve vergelijker: Topical PUVA
This single-blinded randomized bilateral left to right controlled comparison clinical trial of 24 weeks duration will compare the efficacy of NB-UVB to t-PUVA.
For each patient one hand will be randomly assigned to receive t-PUVA and the other hand will receive NB-UVB.
Each hand will receive treatment with either NB-UVB or topical PUVA three times weekly.
Treatment will be performed until complete or almost complete clearing of psoriasis/eczema or until 50 exposures (over 16 weeks) have been reached, whichever comes first.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
The primary endpoint will be based on the change in visual cutaneous symptoms as measured by the modified ASI score
Tijdsspanne: Baseline, every four weeks up to 16 weeks, and at 24 weeks
|
Baseline, every four weeks up to 16 weeks, and at 24 weeks
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
The overall change in physical appearance of the hand will be assessed by the global assessment
Tijdsspanne: Every four weeks up to 16 weeks, and at 24 weeks
|
Every four weeks up to 16 weeks, and at 24 weeks
|
Adverse effects will be assessed every four weeks, including erythema, pruritus, and tanning. This will be assessed using the following scale: 0=none, 1=mild, 2=moderate, 3=severe.
Tijdsspanne: Every four weeks up to 16 weeks
|
Every four weeks up to 16 weeks
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Harvey Lui, MD, FRCPC, University of British Columbia
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Verwacht)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- H12-02854
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Vitiligo
-
PfizerWervingStabiele niet-segmentale vitiligo | Actieve niet-segmentale vitiligoVerenigde Staten, Spanje, Australië, Mexico, Canada, China, Japan, Italië, Kalkoen, Korea, republiek van, Duitsland, Zuid-Afrika, Polen, Verenigd Koninkrijk, Bulgarije
-
PfizerWervingStabiele niet-segmentale vitiligo | Actieve niet-segmentale vitiligoJapan, Canada, China, Verenigde Staten
-
Fundació Institut de Recerca de l'Hospital de la...Voltooid
-
Cairo UniversityGeschorstVitiligo, gegeneraliseerdEgypte
-
Assiut UniversityOnbekend
-
University of TorontoCanadian Interdisciplinary Network Complementary & Alternative Medicine ResearchVoltooid
-
University Hospital, GhentNovartisVoltooidVitiligo vulgarisBelgië
-
Merck Sharp & Dohme LLCWervingNiet-segmentale vitiligoVerenigde Staten, Canada, Australië, Korea, republiek van, Zwitserland, Duitsland, Spanje, Chili, Frankrijk, Israël, Nederland, Japan, België
-
Incyte CorporationWervingNiet-segmentale vitiligoDuitsland, Verenigde Staten, Italië, Polen, Canada, Frankrijk, Bulgarije, Hongarije, Verenigd Koninkrijk